The FDA has approved Apple's sleep apnea detection feature. Sleep apnea is a sleep disorder that causes a person's breathing to repeatedly stop and start throughout the night. The feature is ...

Apple this month received approval to launch the Apple Watch's sleep apnea notifications feature in Malaysia, as noted by local resident Xavier Naxa.It is unclear when the feature will actually ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans and is often treated with a CPAP machine, but is often declined due to ...

Obstructive sleep apnea occurs when a person’s upper airway becomes blocked, which can lead to pauses in breathing during sleep. Symptoms include snoring and fatigue, making the condition easily ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain ...

Dec. 23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep ...

The FDA approval comes amid growing discussion about the potential uses of weight loss drugs beyond treating obesity and diabetes. In addition to sleep apnea, there has been increasing interest in ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

Zepbound’s biggest competitor, Novo Nordisk’s weight loss drug Wegovy, has also been forecast to reduce the prevalence of obstructive sleep apnea 10.7% by 2030.